Biotechnology - Neurological, Pfizer

Filter

Current filters:

NeurologicalPfizer

Popular Filters

Appeals Court rules against EMD Serono over Rebif deal with Pfizer

16-04-2013

Germany's Merck KGaA (MRK: DE) says that a Pennsylvania appeals court has ruled against Merck in deciding…

BiotechnologyEMD SeronoLegalMarkets & MarketingMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebif

Repligen in $70 million deal with Pfizer for SMA program

04-01-2013

USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

US FDA approves Merck KGaA's Rebif Rebidose

04-01-2013

German drug major Merck KGaA's (MRK: DE) US subsidiary EMD Serono and pharma behemoth Pfizer (NYSE: PFE)…

BiotechnologyEMD SeronoMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebifRegulation

Intellect Neurosciences appeals European patent decision

15-12-2011

US neuro drug discovery firm Intellect Neurosciences (OTCBB: ILNS) says that it has filed an appeal regarding…

bapineuzumabBiotechnologyElanIntellect NeuroscienceLegalNeurologicalPatentsPfizerPharmaceutical

Back to top